ALACHUA, Fla.--(BUSINESS WIRE)--The Florida-based biotechnology firm Oragenics (OTCBB:ORNI) (NYSE Alternext Paris:ALONI) announces that it continues to seek strategic alternatives to fund its continuing operations. These alternatives include, but are not limited to, raising capital through the sale of equity, the sale of specific business units, and the sale of the entire Company. If our efforts are unsuccessful, we may be forced to discontinue operations and liquidate the Company’s assets.
